Exploring Different Approaches to Disc-Related Back Pain

 

Physicians treating patients with discogenic back pain continue to evaluate minimally invasive treatment options designed to address different aspects of intervertebral disc degeneration.​

​

Several intradiscal procedures have emerged, each involving different biological materials, proposed mechanisms, and levels of clinical evidence.

​

BioDisc introduces a different approach for physicians to evaluate: a placental-derived extracellular matrix, described as predominantly Type I and Type III collagen, with a proposed role in supporting the structural environment of the annulus fibrosus.

​

Understanding these differences can help physicians assess the available research and determine which approaches warrant further consideration.

​

1. VIA Disc NP — Nucleus Pulposus Supplementation

​

VIA Disc NP utilizes processed, donated human nucleus pulposus tissue administered directly into the intervertebral disc.​

​

Primary approach: Supplement the native nucleus pulposus with allograft tissue.

Early clinical studies have reported improvements in pain and function, although larger controlled studies are needed to establish efficacy.

​

How BioDisc differs: Rather than supplementing the nucleus pulposus with donated disc tissue, BioDisc uses a placental-derived collagen matrix with a proposed annular-support function. 

​

​

2. PRP — Platelet-Rich Plasma

​

PRP is prepared from a patient's own blood and concentrates platelets containing growth factors and signaling proteins.​

​

Primary approach: Investigate whether platelet-derived factors can influence inflammation and tissue-repair processes within the disc.​

​

Published intradiscal PRP studies have produced mixed results, including a randomized trial that found no significant benefit over a control injection at 12 months.​

​

How BioDisc differs: PRP is an autologous, growth-factor-based approach. Bio Disc is a donor-derived extracellular matrix approach, with a different proposed biological function.

​

​

3. BMAC — Bone Marrow Aspirate Concentrate

​

BMAC is obtained from a patient's bone marrow, typically from the pelvis, and contains a mixture of cells and biological signaling components.​

​

Primary approach: Investigate whether concentrated marrow-derived cellular components can influence the degenerative disc environment.​

​

BMAC remains under clinical investigation. A 2025 randomized, sham-controlled study did not demonstrate superiority over the sham procedure.​

​

How Bio Disc differs: BMAC focuses on marrow-derived cells and signaling components. Bio Disc instead introduces an extracellular collagen matrix. 

​

4. Intradiscal Corticosteroid Injections

​

​

Corticosteroids have been injected directly into selected symptomatic intervertebral discs to address inflammation.​

​

Primary approach: Reduce inflammation and potentially provide pain relief.

Clinical reviews suggest that selected patients may experience short-term improvement, although durable benefit has not been established.​

​

How BioDisc differs: Corticosteroid injections primarily target inflammation. Bio Disc is proposed as a matrix-based approach rather than an anti-inflammatory medication.

​

5. Intradiscal Fibrin Sealant

​

​

Fibrin sealants have been investigated for use in discs with internal disruption or annular fissures.

Primary approach: Introduce a fibrin-based material intended to help seal or stabilize damaged areas.​​

​

Early clinical studies have explored possible improvements in pain and function, but the evidence remains limited.​

​

How BioDisc differs: Fibrin sealants are designed around a sealing mechanism. Bio Disc is described as a collagen-rich extracellular matrix with a proposed structural-support role. 

​

Why Should Physicians Explore Bio Disc?

​

BioDisc represents a distinct tissue-derived matrix approach within the developing field of intradiscal biologic procedures.​

​

For physicians already familiar with PRP, BMAC, nucleus pulposus supplementation, or other interventions, Bio Disc raises additional questions worth evaluating:

• How does a placental-derived collagen matrix behave within the intervertebral disc?

• Can matrix-based approaches provide clinically meaningful benefits?

• Which patients, if any, are appropriate candidates?

• What product-specific evidence supports safety and effectiveness?

• What regulatory, coding, and reimbursement considerations apply?

​

Interested in Learning More About Bio Disc?

​

TRIAD Advanced Directions works with physicians interested in reviewing Bio Disc's composition, proposed mechanism, product documentation, emerging research, and practical considerations.

Contact TRIAD Advanced Directions for physician-focused information and to discuss opportunities for further clinical evaluation.​

​

For professional education. Intradiscal biologic procedures may be investigational. Regulatory status, authorized uses, safety, clinical evidence, and insurance coverage must be evaluated for each specific product and procedure. No comparative superiority or clinical outcome is implied.